Jilin Province Boda Weiye Pharmaceutical Co., Ltd. was designated as a provincial-level technology innovation pilot center, a provincial-level technology innovation platform, and a municipal-level science and technology innovation center in 2016.

In 2016, Jilin Boda Weiye Pharmaceutical Co., Ltd. was successively recognized with prestigious titles such as the Provincial Technology Innovation Pilot Center, Provincial Technology Innovation Platform, and Municipal Science and Technology Innovation Center.

Jilin Boda Weiye Pharmaceutical Co., Ltd. is an enterprise integrating product R&D, manufacturing, sales, and technology promotion. Its primary business areas include the production and sale of chemical pharmaceuticals, the development of new drugs, technology transfer, and technical consulting services. The company covers a site area of 100,000 square meters, with total assets worth 200 million yuan and employs 235 people. Equipped with top-tier, cutting-edge technical talent domestically, the company has cultivated robust new-product R&D capabilities through independent innovation as well as strategic external collaborations. The company boasts 2,800 square meters of versatile, state-of-the-art research facilities, complemented by advanced laboratory equipment valued at 30 million yuan. Currently, it has 85 dedicated researchers and development professionals. The company’s core focus lies in pioneering innovative drugs targeting cardiovascular and cerebrovascular diseases, anti-cancer therapies, digestive system disorders, and neuropsychiatric conditions—particularly in the fields of chemical and biopharmaceuticals, where it is committed to developing groundbreaking medications and rapidly scaling up the production of internationally patented products nearing expiration. Boda Weiye Pharmaceutical enjoys a strong foundation for pilot-scale testing and industrialization. It has established production lines compliant with both the latest GMP standards and EU guidelines, capable of manufacturing a wide range of dosage forms—including tablets, capsules, granules, small-volume injections, infusions, and lyophilized powder injections—as well as comprehensive workshops for chemical APIs and intermediates. This enables the company to seamlessly transition from pilot-scale production of active pharmaceutical ingredients to large-scale manufacturing of APIs meeting world-class quality standards, thereby providing robust support for Jilin Province’s "Chemical Pharmaceutical R&D Pilot Base."